New! View global litigation for patent families

WO1992017167A1 - Oral delivery systems for microparticles - Google Patents

Oral delivery systems for microparticles

Info

Publication number
WO1992017167A1
WO1992017167A1 PCT/AU1992/000141 AU9200141W WO1992017167A1 WO 1992017167 A1 WO1992017167 A1 WO 1992017167A1 AU 9200141 W AU9200141 W AU 9200141W WO 1992017167 A1 WO1992017167 A1 WO 1992017167A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
carrier
microspheres
complex
substance
molecule
Prior art date
Application number
PCT/AU1992/000141
Other languages
French (fr)
Inventor
Gregory John Russell-Jones
Steven William Westwood
Original Assignee
Biotech Australia Pty. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5169Proteins, e.g. albumin, gelatin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery

Abstract

There are disclosed complexes and compositions for oral delivery of a substance or substances to the circulation or lymphatic drainage system of a host. The complexes of the invention comprise a microparticle coupled to at least one carrier, the carrier being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of the host, and the microparticle entrapping or encapsulating, or being capable of entrapping or encapsulating, the substance(s). Examples of suitable carriers are mucosal binding proteins, bacterial adhesins, viral adhesins, toxin binding subunits, lectins, Vitamin B12 and analogues or derivatives of Vitamin B12 possessing binding activity to Castle's intrinsic factor.

Description

ORAL DELIVERY SYSTEMS FOR MICRO? ARTICLES

TECHNICAL FIELD

The present invention relates to complexes and compositions for oral delivery of a substance.s) to the circulation or lymphatic drainage system of a host. The invention also relates to processes for the production of complexes and compositions for oral delivery of a substance(s) to the circulation or lymphatic drainage system of a host. The invention further relates to a method of delivering a substance(s) to the circulation or lymphatic drainage system of a host. In addition the invention relates to kits for preparing complexes for oral delivery of a substance(s) to the circulation or lymphatic drainage system of a host.

BACKGROUND ART A number of clinical conditions of vertebrates have sufficiently deleterious effects upon the vertebrate to warrant the administration of some pharmaceutically active agent. Such agents may include (i) vaccines, to protect against diseases such as tetanus, diptheria or whoophing cough, (ii) hormones, e.g. insulin, LHRH, vasopressin, oxytocin, or (iii) drugs, e.g. anti- cancer agents, antibiotics. In these cases, a suitable agent is administered to the vertebrate to invoke immunity, to supplement hormone levels, to eliminate the disease causing agent or to provide a therapeutic effect.

Administration of the pharmaceutical to the vertebrate may be via a number of routes including intramuscular (i.m.), subcutaneous (s.c), or oral (per os, p.o.) administration. I.m. or s.c. administration of the pharmaceutical suffers from the disadvantages that: relatively specialized skills are required to administer the pharmaceutical; large scale administration may be difficult to perform; it is expensive; and a number of side reactions can occur to the agent being administered. For' these reasons oral administration of the pharmaceutical is generally preferred. Many antibiotics (tetracycline, penicillin etc), and hormones (progesterone, oestrogen etc) can be successfully administered via the oral route. There are however drugs, hormones and immunogens whose efficacy is almost totally lost upon oral administration (including Calcitonin, Erythropoetin, Granulocyte Colony Stimulating Factor, Stem Cell Factor, Granulocyte Colony Stimulating Factor, LHRH analogues, Somatostatin, Insulin, Interferons, Plasminogen Activator Inhibitors and species of DNA and RNA). This loss of efficacy may be due either to the inability of the intestinal mucosa to absorb these compounds or the breakdown of these substances by various physiological agents in the intestinal milieu. To some extent this effect can be overcome by the administration of extremely large doses of the pharmaceutical agent. This approach, however, is not economically feasible for many pharmaceutical agents.

In an attempt to overcome the problem of degradation a number of encapsulation methods have been employed which enable the encapsulated material to by-pass both the gastric acidity and the pepsin mediated proteolysis encountered within the lumen of the stomach. Typically these methods have involved enteric coated capsules, which only release their contents upon contact with the higher pH of the upper duodenum and jejunum. While this has greatly increased the oral efficacy of a number of compounds, still many substances are pharmaceutically inactive upon ora! delivery and must be administered parenterally. Noteable examples of such compounds include Calcitonin, Erythropoietin, Granuiocye Colony Stimulating Factor, Stem Cell factor, Granulocyte Macrophage Colony Stimulating Factor, Somatostatin, Insulin, LHRH and its analogues, Interferons, Plasminogen Activator Factor, species of DNA amn RNA, and many vaccines.

In a further extension of the encapsulation process, several new forms of encapsulation have been designed in recent years with the specific purpose of trapping large quantities of pharmaceuticals in subcelluiar capsules, in the hope that once protected from the intestinal milieu, the capsules would themselves be taken up from the intestine and release their contents systemically. Two basic forms of these capsules have been developed, nanocapsules (or microcapsules) and nanospheres (or microspheres). In essence these particles can be formed by one of a number of methods, several of which are outlined below: (i) Solvent Evaporation

In which a compound which is soluble in one solvent is dispersed into a non-miscible solvent and the first solvent is evaporated off. Particles formed in this fashion have been used to administer (parenterally) a number of water insoluble compounds. An example of such a system would be the formation of polyalkylcyanoacrylate nanocapsules in which the antifungal agent, griseofulvin is entrapped. Hi) Desolvation

In this method a compound is contained in a liquid in which it is soluble (the solvent) and a second liquid (which is miscible with the first liquid, but in which the compound is not soluble) is added to the solvent. As more of the second liquid is added the compound becomes desolvated. During the process of desolvation the compound rich phase (the coacervate) contains an enriched amount of compound which is dispersed as microdroplets in the compound deficient phase. At this stage the coalesced material can be chemically crossiinked by a suitable crosslinking agent to form micro or nano-particles.

Nanoparticles of gelatin or BSA can be prepared in this way. Solutions of these proteins are desolvated by the addition of sodium suifate, or ammonium sulfate solutions. At the point of desolvation there is an increase in turbidity, at which time the nanoparticles can be formed by the addition of a suitable cross-linker such as giutaraldehyde or butanedione.

(iii) Complex coacervation in this procedure two polyelectrolytes having opposite charge are mixed in aqueous medium so that a spontaneous liquid/liquid phase separation occurs. The phenomenon is limited to polymers having a suitable ionic charge density and chain length. Typically these microspheres are formed by the addition of a polyanion such as Gum Arabic, Alginate, or Polyphosphate, to a polycation such as Gelatin.

(iv) Po/vmer/oo/vmer inco oatabilitv This procedure is based upon the observation that two chemically different polymers dissolved in a common solvent are usually incompatible.

Thus the mixture will tend to form two phases. The insoluble phase can be used to coat core particles to form microcapsules. An example would be the precipitation of ethyl cellulose from cyclohexane by the addition of polyethylene.

(v) Interfacial Polymerization

In this technique, two reactants, each dissolved in a mutually immiscible liquid, diffuse to the interface between the two liquids where they react to form a capsule wall. An example of such capsule formation would occur if a mixture of Sebacoyl chloride dissolved in an oil phase was emulsified into an aqueous phase containing ethγlenediamine.

Oppenheim and coworkers (1982) have used the desolvation process (described above) to prepare insulin nanoparticles. These nanoparticles were found to be highly effective when administered intravenously, however a disappointingly small quantity of insulin was delivered to the systemic circulation when these particles were given orally. It would appear, from this work that although it was possible to protect the insulin from degradation in the intestine it was not possible to target the nanoparticles to the intestinal mucosa in such a way as to cause uptake. The lack of a suitable targetting agent has in fact rendered this type of microencapsulation technique to be generally unsuitable for oral delivery of encapsulated agents.

Recent work in part undertaken by one of the current inventors (W086/06635 and PCT/AU86/00299, the disclosures of which are incorporated herein by reference) has, however, provided such a targettin mechanism. In this work use was made of two natural uptake mechanisms i the gut. The "first mechanism utilizes the natural uptake mechanism for Vitami B12. During this uptake Vitamin B12 firstly binds to intrinsic factor (IF) in the upper small intestine. The Vitamin B1 -iF complex then passes down the smal intestine and binds to an IF receptor located on the surface of the iiea epithelium. The whole Vitamin B12-IF-receptor complex is then internalized b receptor-mediated endocytosis and some time later the Vitamin B-»2 appears in the serum. It has been shown that it is possible to chemically link peptides to Vitamin B-] 2 in such a manner that does not interfere with its complexing to IF, and to deliver these molecules to the circulation following oral administration. The use of Vitamin B12 as a carrier for the oral delivery of active substances is described in PCT/AU86/00299.

In the second mechanism, natural mucosal binding proteins were employed to target various haptens and protein molecules to the gastrointestinal mucosa and elicit their uptake. These binding proteins included bacterial adhesins (987P and 99 piii), a viral adhesin (flu virus), a toxin binding subunit (LTB), as well as a number of plant lectins. This class of molecules was termed carrier molecules. Both the above described mechanisms do however suffer from the disadvantage that the amount of material which could be delivered through either uptake mechanism was directly proportional to the amount of targetting agent which could be taken up. In this regard, the vitamin B12 uptake mechanism is limited by the absolute quantity of Vitamin B12 which is normally absorbed, which in most animals amounts to only a few micrograms.

Furthermore, in order for either carrier system to work effectively the conjugated material (hormone, peptide or drug) must preferably be able to survive the proteolytic environment of the small intestine and must also contain a suitable site for chemical cross-linkage to the carrier. During the conjugation, care must be taken to preserve the pharmacological activity of the active agent both during the conjugation as well as in the final complex. Furthermore, a number of peptides may not be suitable for oral delivery (due to sensitivity to proteolysis, or due to lack of suitable functional groups for conjugation) and so new analogues may need to be developed which possess an appropriate conjugation site or have been designed to resist proteolytic degradation. In this respect the present invention can be distinguished from the previous inventions described above in that the carrier molecule of the present invention is ΠQI covalently conjugated to the pharmaceutically active agent, but rather the carrier molecule is either covalently linked to the material/polymer comprising the microsphere, or is associated hydrophobically with the surface of the microsphere during its formation.

Surprisingly, the present inventors have discovered that it is possible to prepare complexes comprising at least one carrier molecule and at least one microparticle comprising an active pharmaceutical agent. More surprisingly, the present inventors have discovered that the carrier in such complexes can enable the complex comprising a relatively large microparticle to be transported to the circulatory or lymphatic drainage system via the mucosal epithelium of a host. Thus, the present invention overcomes the above- described disadvantages of the methods of oral delivery of the prior art, since in the complexes of the present invention the active agent is not chemically modified and its physiological activity is preserved while the microparticle provides a protection against degradation or modification in the gastro¬ intestinal environment. Furthermore, the microparticies of the invention are linked to a carrier molecule which can specifically target the microparticies to the intestinal epithelium and provoke uptake.

Other advantages of the present invention will be apparent from the objects of the invention and the disclosure of the invention hereinbelow.

OBJECTS OF INVENTION Objects of this invention are to provide complexes and compositions for oral delivery of a substance(s) to the circulation or lymphatic drainage system of a host.

Other objects are to provide processes for the production of complexes and compositions for oral delivery of a substance(s) to the circulation or lymphatic drainage system of a host, a method of delivering a substance(s) to tne circulation or lymphatic drainage system of a host and kits for preparing complexes for oral delivery of a substance(s) to the circulation or lymphatic drainage system of a host.

DISCLOSURE OF INVENΗON The term "carrier" as used throughout the specification includes mucosal binding proteins, Vitamin B 2, and analogues or derivatives of Vitamin B12 possessing binding activity to Castle's intrinsic factor, and aiso includes within its meaning the expression "carrier molecule".

The term microparticle as used throughout the specification includes microspheres and microcapsules and refers a small particle ranging in size from 1 nanometer to 100 micrometers in diameter.

According to a first embodiment of this invention there is provided a complex for oral delivery of a substance to the circulation or lymphatic drainage system of a host, comprising: a microparticle coupled to at least one carrier; the carrier being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of the host; the microparticle entrapping or encapsulating the substance whereby the substance is substantially unaffected by intestinal digestive substances of the host; and the microparticle being adapted to release the entrapped or encapsulated substance into the circulation or lymphatic drainage system of the host.

A particularly desired form of the complex of the first embodiment of the present invention is a microsphere or microcapsule coupled to a carrier molecule, the microsphere or microcapsule enclosing a hormone, drug, immunogen, or DNA or RNA (such as ribozyme) component, molecule or analogues thereof, wherein the carrier molecule is a mucosal binding protein or Vitamin B12, or an analogue or derivative of Vitamin B12 possessing binding activity to Castle's intrinsic factor.

According to a second embodiment of this invention there is provided a complex for oral delivery of a substance to the circulation or lymphatic drainage system of a host, comprising: a microparticle coupled to at least one carrier; the carrier being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of the host; the microparticle being capable of entrapping or encapsulating the substance whereby the substance is substantially unaffected by intestinal digestive substances of the host; and the microparticle being adapted to release the entrapped or encapsulated substance into the circulation or lymphatic drainage system of the host.

In the first and second embodiments each microparticle may have a single carrier coupled to it.

Alternatively, in the first and second embodiments a plurality of carriers which may be the same or different may be coupled to the microparticle. Alternatively, a plurality of microparticies which may be the same or different and which may contain the same substance or different substances may be coupled to the carrier. Typically, the plurality of carriers is from 2 to 100000, generally from 2 to 10 and typically from 2 to 5. Advantageously, the plurality of microparticies is from 2 to 10 and typically from 2 to 4. Other molecules may be coupled to the microparticle as long as they do not substantially prevent the carrier from being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of the host. Such molecules include targetting molecules which target and attach the complex of the first embodiment to or in the vicinity of a desirable target in the host (eg an organ in the host). A carrier molecule which also functions as a targetting molecule may also be used. Examples of targetting molecules include antibodies (including monoclonal and poiycional antibodies), lectins, enzymes, or other binding proteins or substances (or binding fragments thereof).

According to a third embodiment of this invention there is provided a composition for oral delivery of a substance or substances to the circulation or lymphatic drainage system of a host, comprising a mixture of a plurality of different complexes according to the first embodiment. The complexes may be different in that the carrier, the microparticle and/or the substance of each complex may be different to the carrier, the microparticle and/or the substance of at least one of the other complexes.

The composition of the third embodiment can also include an acceptable carrier, diluent, excipient and/or adjuvant. According to a fourth embodiment of this invention there is provided a composition for oral delivery of a substance to the circulation or lymphatic drainage system of a host, comprising the complex of the first embodiment together with a physiologically acceptable carrier, diluent, excipient and/or adjuvant. According to a fifth embodiment of this invention there is provided a process for preparing a composition for oral delivery of a substance to the circulation or lymphatic drainage system of a host, comprising: mixing a complex of the first embodiment with at least one different complex of the first embodiment. The process of the fifth embodiment can further include mixing a physiologically acceptable carrier, diluent, excipient and/or adjuvant with the complex and the least one different complex.

A preferable composition of the fifth embodiment is a medicament comprising a carrier coupled to a microsphere or microcapsule comprising a hormone, drug, immunogen or DNA or RNA (such as ribozyme) component, molecule or analogues thereof in pharmaceutically active form.

According to a sixth embodiment of this invention there is provided a process for preparing a composition for oral delivery of a substance to the circulation or lymphatic drainage system of a host, comprising: mixing the complex of the first embodiment with a physiologically acceptable carrier, diluent, excipient and/or adjuvant.

The nature of the carrier, diluent, excipient and/or adjuvant utilised i the composition of the third embodiment is dependent on the type of host. For instance, when the host is a human the carrier, diluent, excipient and/or adjuvant is pharmaceutically acceptable. When the host is non human such as an a non human mammal (eg a dog, cat, sheep, goat cow, bull, camel or horse) or other animal, the carrier, diluent, excipient and/or adjuvant is veterinarilly acceptable. Examples of pharmaceutically acceptable carriers, diluents ana excipients for oral delivery include : sodium bicarbonate solutions and similar diluents which neutralise stomach acid or have similar buffering capacity, glycols, oils or emulsions; and include medicaments in the form of geis, pastes and viscous colloidal dispersions. The medicament may be presented in capsule, tablet, slow release or elixir form or as a gel or paste. Furthermore the medicament may be presented as a food.

According to a seventh embodiment of this invention there is provided a method of orally delivering a substance to the circulation or lymphatic drainage system of a host requiring such substance, comprising: orally administering to the host an effective amount of a complex of the first embodiment or a composition of the third or fourth embodiments.

A preferred method of the seventh embodiment is for treating a vertebrate host by administration of a hormone, drug, immunogen or DNA or RNA (such as ribozyme) component, molecule, analogue or derivative thereof requiring such administration which method comprises the oral administration to the host of an effective amount of a carrier coupled to a microsphere or microcapsule comprising a hormone, drug, immunogen or DNA or RNA (such as ribozyme) component, molecule, analogue or derivative thereof appropriate to the therapy of the host. According to an eighth embodiment of this invention there is provided a kit for preparing a complex for oral delivery of a substance to the circulation or lymphatic drainage system of a host, comprising: at least one type of carrier; at least one type of microparticle; means to couple the microparticle to the carrier to form the complex; the carrier being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of tne host; the microparticle entrapping or encapsulating the substance whereDy the substance is substantially unaffected by intestinal digestive substances of the host; and the microparticle being adapted to release the entrapped or encapsulated substance into the circulation or lymphatic drainage system of the host.

The kit may include a plurality of the same or different carriers and/or s plurality of the same or different microparticies. The microparticies may contain the same substance or different substances. The kit may include a: least one type of auxiliary molecule such as a targetting molecule and means to couple the auxiliary molecule(s) to the microparticle(s).

Hormones, drugs, immunogens or DNA or RNA (such as ribozyme) component, molecule or analogues thereof suitable to be incorporated within ε microparticle, such as a microsphere or microcapsule include all hormones, drugs, immunogens or DNA or RNA (such as ribozyme) component, molecule or analogues thereof for which oral administration is desirable but for whicn oral administration in an unprotected form results in substantial loss of efficacy.

Thus typical substances for delivery according to the invention include active substances such as hormones and bioactive peptides (and analogues and derivatives thereof) such as LHRH, Vasopressin, oxytocin, Insulin, testosterone, interferon, somatotrophin, somatostatin, Erythropoietin, Colony Stimulating factors (G-CSF, GM-CSF, CSF), PMSG, HcG, inhibin, PAI-ll; therapeutic agents such as neomycin, salbutamol, pyrimethamine, penicillin G, methicillin, cabenicillin, pethidine, xylazine, ketamin HCI, mephensin, GABA, iron dextran, nucleotide analogues or ribozyme.

Further examples of active substances include polypeptides such as insulin, somatostatin, somatostatin derivatives (U.S. Pat. Nos. 4,087,390, 4,093,574, 4,100,117 and 4,253,998), growth hormones, prolactin, adrenocorticotropic hormone (ACTH), melanocyte stimulating hormone (MSH), thyroid hormone releasing hormone (TRH), its salts, and derivatives thereof (U.S. Pat. Nos. 3,957,247 and 4,100,152), thyroid stimulating hormone (TSH), luteinizing hormone (LH), follicle stimulating hormone (FSH), vasopressin, vasopressin derivatives [desmopressin {Folia Endocrinoiogica Japonica 54, No. 5, p. 676-691 (1978)]]. oxytocin, calcitonin, paratnyroid hormone, glucagon, gastrin, secretin, pancreozymin, cholecystokinin, angiotensin, human piacental lactogen, human chorionic gonadotropin (HCGj, enkephaiin, enkephalin derivatives [U.S. Pat. No. 4,277,394, European paten: application Publication No. 31567], endorphin, kyotorphin, interferons la, _.. g), interleukins (I, II, and III), tuftsin, thymopoietin, thymosin, thymostimulin, thymic humoral factor (THF), serum thymic factor (FTS), and its derivatives (U.S. Pat. No. 4,229,438) and other thymic factors [Medicine in Progress 125, No. 10, p. 835-843 (1983)1, tumor necrosis factor (TNF), colony stimulating factor (CSF), motilin, dinorphin, bombesin, neurotensin, ceruiein, bradykinir,, urokinase, asparaginase kallikrein, substance P analogue and antagonist, nerve growth factor, blood coagulation factors VIII and IX, lysozyme chloriαe. polymixin B, colistin, gramicidin, bacitracin, protein synthesis stimulating peptides (British patent No. 8232082), gastric inhibitory poiypeptide (GIP), vasoactive intestinal poiypeptide (VIP), platelet-derived growth factor (PDGF), growth hormone releasing factor (GRF, somatocrinin), bone morphogenetic protein (BMP), epidermal growth factor (EGF), etc.

Examples of antitumor agents include bleomycin hydrochioriαe, methotrexate, actinomycin D, mitomycin C, vinblastine sulfate, vincristine sulfate, daunorubicin hydrochloride, adriamycin, neocarcinostatin, cytosine arabinoside, fluorouracil, tetrahydrofuryl-5- fluorouracil, krestin, picibanil, lentinan, levamisole, bestatin, azimexon, glycyrrhizin, poly l:C, poiy A:U and poly ICLC.

Examples of antibiotics, include gentamicin, dibekacin, kanendomycin, lividomycin, tobramycin, amikacin, fradiomycin, sisomicin, tetracycline hydrochloride, oxytetracyciine hydrochloride, roiitetracyciine, doxycycline hydrochloride, ampicillin, piperacillin, ticarcillin, cephalothiπ, cephaioridine, cefotiam, cefsulodin, cefmenoxime, cefmetazoie, cefazolin, cefotaxime, cefoperazone, ceftizoxime, moxolactam, latamoxef, thienamycin, sulfazecin, and azthreonam.

The aforementioned antipyretic, analgesic and antiinflammatory drugs include, for instance, sodium salicylate, sulpyrine, sodium flufenamate, sodium diclofenac, sodium indomethacin, morphine hydrochloride, pethidine hydrochloride, levorphanol tartrate and oxymorphone. Examples of the antitussives and expectorants may be mentioned ephedrine hydrochloride, methylephedriπe hydrochloride, noscapine hydrochloride, codeine phosphate, dihydrocodeine phosphate, alloclamide hydrochloride, chlophedianol hydrochloride, picoperidamine hydrochloride, cloperastine, protokylol hydrochloride, isoproterenol hydrochloride, salbutamol sulfate and terbutaline sulfate. Examples of sedatives include chlorpromazine hydrochioride, prochlorperazine, trifiuoperazine, atropine sulfate and scopoiamine methylbromide. The muscle reiaxants include, among others, pridinol methanesulfonate, tubocurarine chloride and pancuronium bromide. The antiepileptics include, for instance, sodium phenytoin, ethosuximide, sodium acetazolamide and chlordiazepoxide hydrochloride. Examples of antiulcer drugs include metoclopramide and L-histidine monohydrochloride. Examples of antidepressants include imipramine, clomipramine, noxiptiline and phenelzine sulfate. The antiallergic drugs include, among others, diphenhydramine hydrochloride, chlorpheniramine maleate, tripelenamine hydrochloride, methdilazine hydrochloride, clemizole hydrochloride, diphenylpyraline hydrochloride and methoxypheπamine hydrochloride. The cardiotonics include, among others, trans- p - oxocamphor, theophylloi, aminophylline and etilefrine hydrochloride. The antiarrythmic agents include, for instance, propranolol hydrochloride, alprenolol hydrochloride, bufetolol hydrochloride and oxyprenolol hydrochloride. The vasodilators include, among others, oxyfedrine hydrochloride, diltiazem hydrochloride, tolazoline hydrochloride, hexobendine and bamethan sulfate. The antihypertensive diuretics include, among others, hexamethonium bromide, pentolinium, mecamlamine hydrochloride, ecarazine hydrochloride and clonidine hydrochloride. Examples of antidiabetics include sodium glymidine, glypizide, phenformin hydrochloride, buformin hydrochloride and metformin. The anticoagulants include, among others, sodium heparin and sodium citrate. The haemostatic agents include, among others, thromboplastin, thrombin, menadione sodium bisulfite, acetomenaphthone, e-amino-caproic acid, tranexamic acid, carbazochrome sodium sulfonate and adrenochrome monoaminoguanidine methanesulfonate. Among antituberculotics are isoniazid, ethambutol and sodium p- aminosaiicyiate. The hormone drugs are exemplified by prednisolone succinate, prednisolone sodium phosphate, dexamethasone sodium sulfate, betamethasone sodium phosphate, hexestrol phosphate, hexestrol acetate and methimazole. The antinarcotic agents include, among others, levailorphan tartrate, nalorphine hydrochloride and naloxone hydrochloride.

Suitable carrier molecules include Vitamin B12, a Vitamin B12 analogue or derivative (as described in PCT/AU 86/00299), or a lectin, or "lectin-like" molecule (such as that described in W086/06635).

Suitable carrier molecules also include bacterial adhesins, viral adhesins, toxin binding subunits and lectins, as well as Vitamin B12 and analogues thereof.

Analogues of Vitamin B12 for use as carriers for microparticies include cyanocobatamin, aquocobalamin, adenosylcobalamin, methyicobaiamin, hydroxycobalamin, cyanocobalamin carbanalide, 5-O-methylbenylcobalamin, and the desdimethyl, monoethylamide and methylamide analogues of all of the preceding analogues, as well as coenzyme B12, δ'-deoxyadenosylcobaiamin, chlorocobalamin, sulfitocobamin, nitrocobalamin, thiocyanatocobalamin, 5,6- dichlorobeπzimadazole, 5-hydroxybenzimidazole, trimethylbenzimidazole, adenosylcyanocobalamin, cobalamin lactone, cobalamin iactam, and analogues in which the cobalt is replaced by zinc or nickel or the corrin ring is replaced by a substituent which does not affect the binding capacity of the analogue to IF.

Derivatives of Vitamin B12 for use as carriers for microparticies include the anilide, ethylamide, monocarboxyiic and dicarboxyiic acid derivatives of Vitamin B12 and its analogues as well as tricarboxylic acid or proprionamide derivatives of Vitamin B12 or its analogues. They would also include molecuies in which alterations or substitutions had been performed to the Corrin ring [viz:-cyano (13-epi) cobalamin Co a-(a 5,6-dimethyibeπzimidazoyl)-Co, b- cyaπo-(13-epi) cobamic a,b,c,d,g, pentaamide, adenosγl-10-chiorocobalamin, dicyanobyrinic heptamethyi ester, cyanoaquacobyrinic acid pentaamide], or where cobalt had been replaced by another metal ion (viz:- nickel, zinc, etc) or various anion or alkyl substituents to the corrin ring such that the bindinπ capacity of the molecule to intrinsic factor is unaffected. The mucosal epithelial cells will take up the intrinsic factor-vitamin B12 complex including the microparticle, such as a microsphere or microcapsule attached to the vitamin B12 (or suitable analogue) and transepitheiially transport the microsphere or microcapsule and deliver them into the circulation where the enclosed substance such as a hormone, drug, immunogen, or DNA or RNA (such as ribozyme) component, molecule or analogues thereof can act.

Derivatives and analogues of vitamin B12 are discussed in Schneider, 2. and Stroinski, A.; Comprehensive B12) Waiter De Gruyter; Berlin, NY: 1987, the disclosure of which is incorporated herein by reference.

Similarly, if a microparticle, such as a microsphere or microcapsule is administered orally and complexed to a carrier protein possessing binding activity to the mucosal epithelium, the cells of the mucosal epithelium take up those molecules including the microparticies, such as microspheres or microcapsules attached to the carrier proteins and present the microsphere or microcapsule to the circulation where the substance such as a drug, hormone, immunogen or DNA or RNA (such as ribozyme) component, moiecuie or analogues thereof enclosed therein can act.

Polymers suitable for the formation of microspheres by soiven: evaporation (in liquid drying) include, amongst others, Poly-lactic acid, Poiy- (Lactide/co-glycolide), Poly-hydroxybutyrate, Poly-hydroxyvalerate, Poiy- (hydroxybutyrate/vaierate), Ethyl cellulose, Dextran, Polysaccharides, Poiyalkyicyaπoacrylate, Poly-methyl-methacrylate, poly(e-caprolactone) and various combinations and co-polymers of the above. Polymers suitable for the formation of microspheres by interfacial precipitation/polymerization include, amongst others, EUDRAGIT™; Poly(Na,Ne-L-lysinediylterephthaloyl); polymers formed by the reaction of Lysine hydrochloride and p-phthaioyl dichloride; by the reaction of acryloylated maltodextrin or acryloylated hydroxyethyl starch with ammonium peroxodisulfate and N,N,N',N'-tetramethylethylenediamine. Microspheres can also be formed by the polymerization of various diamines such as ethviene diamine, phenyienediamine, toluene diamine, hexamethylene diamine, or diols such as ethylene diol, bisphenol, resorcinol, catechol, pentanediol, hexanediol, dodecanediol, 1 ,4 butanediol, with diacid chlorides such as sebacoyi chloride and adipoyl chloride, or diisocyanates such as hexamethylene diisocyanate using the methods fully described in EP-A-85870002.4, the disclosure of which is incorporated herein by reference.

Polymers suitable for the formation of microspheres by polymer phase separation include co-poly(vinyl chloride:vinyl alcohol:vinyl acetate), cellulosic polymers, polyvinyl acetate, polyvinyi alcohol, polyvinyichloride, natural and synthetic rubbers, polyacrylates, polystyrene and the like. Methods and materials to synthesize such microspheres are fully described in US Pat. No. 4, 1 66,800, the disclosure of which is incorporated herein by reference. Polymers suitable for the formation of microspheres by complex coacervation include, amongst others, mixtures of polyanions, such as gum arabic, alginate, carboxymethyl cellulose, carboxymethyl starch, polystyrene sulfonic acid, polyvinyl sulfonic acid, poly-giucuronic acid, Poly-pyruvic acid, carrageenan, heparin sulphate, polyphosphate with polycations, such as polylysine, gelatin.

Polymers suitable for the formation of microspheres by Polvmer/Polvmer incomoatabilitv include, amongst others, ethyl cellulose, Ethylene vinyl acetate polymer, Poly(lactide), or Poly(vihylidene chloride) mixed with polymers such as Polyethylene, Silicone, Polyisobutylene or Polybutadiene. Other materials suitable for formation of microspheres include, Starch,

Cross-linked Albumen, Polyacrylamide, Cross-linked gelatin and others obvious to those skilled in the art of microsphere preparation. Materials suitable for the formation of microspheres, and methods for the preparation of microspheres, are described in US Pat. Nos. 3,936,573 and 3,962,414, the disclosures of which are incorporated herein by reference.

According to the present invention there is also provided a process for the production of a complex of the invention, which process comprises one or more of the following steps : (a) reacting microparticies with a carrier molecule to form the complex; (b) chemically modifying a carrier molecule to provide at least one functional group capable of forming a chemical linkage and reacting a microparticle and the modified carrier molecule to form the complex;

(c) reacting microparticies with at least one cross-linking agent and reacting the reacted microparticies with a carrier molecule to form the complex;

(d) reacting a carrier molecule with at least one cross-linking agent and reacting microparticies with the reacted carrier molecule to form the complex;

(e) reacting microparticies and a carrier with at least one cross-linking agent to form the complex; (f) reacting microparticies with at least one cross-linking agent, reacting a carrier molecule with at least one cross-linking agent and reacting the reacted microparticies and the reacted carrier molecule to form the complex; or (g) reacting a carrier molecule with a hydrophobic moiety and reacting microparticies with the reacted carrier molecule to form a complex non- covalently bonded by hydrophobic interaction.

As an example of reaction (g) above, in order to link Vitamin B1 to the surface of microparticies which have no readily available chemical groups suitable for chemical conjugation, it is possible to prepare a complex of Vitamin B12 to an hydrophobic moiety which can insert, non-covalently, into the surface of the microparticies. Such a molecule is easily added at the time of formation of the microparticies. The strength of the hydrophobic association is such that there is only a very slow dissociation of the Vitamin B12 from the microparticies under physiological conditions. Similarly, other carrier molecules may be reacted with hydrophobic moieties, for formation of an hydrophobically-associated complex with a microparticle.

Suitable hydrophobic moieties which can be used for reacting with a carrier molecule are aliphatic or aromatic chains or amphipathics containing a water soluble head and a lipid soluble tail suitable for hydrophobic association within an hydrophobic environment. Examples include oleic acid, octanoic acid, linoleic acid, stearic acid, palmitic acid or glycerophosphoric acids, which may be directly conjugated to an amino group of a carrier molecule using a suitable carbodiimide (for example dicyclohexyicarbodiimide (DCC), or 1-ethyl- 3-(3-dimethylaminopropylcarbodiimide (EDAQ). Similarly, any amphiphathic molecule possessing an amino-group , for example amino-hexane, amino- decane, amino-dodecane, amino-tetradecane, amino-hexadecane or phosphatidyl-ethanolamine, may be conjugated directly to carboxyl groups using carbodiimides.

Alternatively, the carrier molecule may be linked covalently, directly or indirectly to the microparticle. Where a cross-linking agent is used, the cross- linking agent may contain a disulfide bond or be cleavable by acid, base or periodate. Examples of cross-linking agents include N-(4- azidophenylthio)-phthalimide; 4,4'-dithiobisphenylazide; dithio-bis-(succinimidyl-propionate); dimethyl-3,3'- dithio-bis-propionimidate.2HCI; 3,3'-dithio-bis-(sulfosuccinimidyl-propionate); ethyl-(4-azidophenyl)-1 ,3'-dithiopropionate; sulfo-succinimidyl-2-(m-azido-o- nitrobenzamido)-ethyl-1 ,3'-dithiobutyrimidate.HCI; N-succinimidyl-(4- azido-phenyl)-1 ,3'dithiopropionate; sulfo-succinimidyl-2-(m-azido-o- nitro-benzamido)-ethyl-1 ,3'-dithiopropionate; sulfo-succinimidyl-2-(p- azido-salicyiamido)-ethyi-1 ,3'-dithiopropionate; N-succinimidyl-3-(2- pyridylthio)propionate; sulfosuccinimidyl-(4-azidophenyldithio)-propionate; 2- iminothiolane; disuccinimidyl tartrate; bis-[2-(succinimidyloxycarbonyloxy)- ethyil-sulfone and carbodiimides. A description of suitable carbodiimides is provided in horana, H.G. (1953) Chem. Rev. 53: 145-166, the disclosure of which is incorporated herein by reference.

Examples of suitable methods of reacting vitamin B12 (VBι2) derivatives with functionaiised microparticies include: (i). Reaction of carboxy-VB12 with amine

EDAC VB12-COOH + NH2-R = = = > VB12-CONH-R + H20

(ii). Reaction of carboxy-VB^ with phenol

EDAC VB12-COOH 4- HO-Ph-R = = = > VB12-CO-0-Ph-R + H20

(iii) Reaction of amino-VB^ with carboxylates

EDAC VB12-NH2 + COOH-R = = = > ' VB12-NHCO-R + H20

Methods of coupling vitamin B12 derivatives to various functional groups are also described in US Pat. No. 4,465,775, United Kingdom Patent No. 1 ,345,327 and US Pat. No. 3,981 ,863, the disclosures of which are incorporated herein by reference.

Suitable cross-linking of the carrier and the microspheres may be achieved by acid hydrolysis of the amide side groups of the propionamide side chains adjacent to rings A, B, C or D of Vitamin B12 and coupling to suitable side groups of the microspheres.

The carrier molecule or cross-linking agent may react with a functional group or a modified functional group present on, or introduced onto the surface of the microparticle. Suitable functional groups for reaction with the carrier molecule or cross-linking agent include carboxyl, hydroxyl, amino, thio, amido, hydrazo, azido, phenolic, ester, aldehyde, ketone, sulfate, halo, phosphate, isocyanato and isothiocyanato groups. Suitable reagents for modification or introduction of functional groups include hydrazine, periodate, permanganate or other oxidising agents, borohydrides, metallic hydrides or other reducing agents.

Alternatively, a spacer molecule may be used to link the carrier molecule to the microparticle. Examples of such spacer molecules include bifunctional molecules such as diamines, dicarboxyiic acids, diois, aminocarboxylic acids, dithiols, diesters, diphenols, and other like molecules.

Advantageously, using a complex of the present invention, a substance such as a hormone, drug or immunogen can be presented via the mucosai epithelium of a host, in a pharmaceutically active form to the circulation or lymphatic drainage system of a host. Initially, microparticies such as microspheres or microcapsules, containing a substance such as a pharmaceutically active agent, are prepared and linked, generally covalently, to a suitable carrier (generally a mucosal binding protein or Vitamin B12 or an analogue or derivative thereof) such that the carrier maintains its ability to interact with the intestinal mucosa or intrinsic factor (respectively). Then the microparticies are administered orally to a host and as a result of this administration the carrier-microparticles and the substance contained therein pass into the circulation or lymphatic drainage system of the host, in this fashion the substance is protected from the degradative contents of the intestinal milieu, and the uptake capacity of the carrier is amplified. Thus, a complex according to the first embodiment of the preseni invention overcomes the disadvantages inherent in the mucosai binding protein and Vitamin B12 uptake system, viz:- the need for substances, such as pharmaceutical agents, to be resistant to gastro-intestinal enzymes and pH conditions, as well as the limited uptake capacity of the uptake systems. The present invention relies on the ability to entrap substances, which are generally small molecules, such as hormones, proteins, peptides, drugs, etc, within a matrix or capsule, generally fabricated from a suitable polymer, in such a way as to form very small microparticies such as microcapsules or microspheres. Once trapped within these microparticies it is possible using suitable chemistry to link, generally covalently link, these microparticies to a suitable carrier.

A system for oral delivery of an active substance coupled directly to Vitamin B12 is limited in the amount of active substance that can be deiiverec by the uptake capacity of the IF-dependent uptake mechanism. In humans, this mechanism can only deliver 1-2 μg doses of vitamin B12 per feeding (see Cobalamin. Biochemistry and Pathophysioiogy. Ed Babior, B.M., Wiiev- Interscience, NY, 1975.) Similarly, when microencapsulated active agents are administered orally, typically only from 0.1 % to 1 % of the active agent

5 administered is delivered into the bloodstream (Gruber, R. Longer, M.A. and Robinson, K.J.R. 1987: Some Biological issues in Oral Controlled Drug Delivery, Adv. Drug Delivery Rev. 1 : 1 -18).

Using carrier-microparticie complexes of the present invention, however, there is the potential to amplify the uptake of a substance administered orally, some

10 10 to one million times (depending upon the size of microparticle and the loading) as well as to protect the entrapped substance, typically a pharmaceutical agent, from intestinal digestive substances of the host, typically, gastrointestinal enzymes. By choosing a suitable substance for the microparticle such as a bio-degradabie polymer the entrapped substance is

15 released once the carrier mediated uptake system has delivered the carrier- microsphere complex to the circulation.

Amplification of Vitamin B12 uptake capacity by the incorporation of pharmaceutical active agents into microspheres is illustrated in the following Table 1 .

20

Table 1. Amplification of the Vitamin B12 uptake capacity by the incorporation of pharmaceutically active agents into microspheres. Total delivery to man.

1 Data is calculated from the uptake capacity for Vitamin B12 of 1 nanomole per feed in man, which represents 6 X 101^ molecules of Vitamin B12-

2 Each microsphere would be loaded to a 10 % rug loading.

3 With normal unassisted uptake approximately 0.1 - 1 % of the dose of an orally administered pharmaceutical will cross the intestinal wall and enter the circulation. The Vitamin B12 uptake mechanism has the capacity to amplify this uptake by at least one hundred fold.

A particular advantage of the carrier-microparticie complexes of the present invention compared with the carrier-active agent complexes of the prior art is that, there is no chemical modification of the active substance in the complexes of the present invention.

BEST MODE AND OTHER MODES FOR CARRYING OUT THE INVENTION Microspheres containing a substance such as a hormone, drug, immunogen, or DNA or RNA (such as ribozyme) component, molecule or analogues thereof, are prepared typically by one or more of a number of techniques commonly known to those knowledgeable in the art, including :- Solvent evaporation, Complex coacervation. Polymer/polymer incompatibility, Gelation, Interfacial polymerization and Thermal denaturation.

For oral delivery microspheres are complexed with a carrier molecule by direct reaction or by use of cross-linking agents to provide a complex in which the carrier molecule is still able to undergo the binding reactions required for the uptake and transport of the complex and the pharmacological activity of the entrapped active substance is maintained. The carrier molecule is a mucosal binding protein or Vitamin B12, or an analogue or derivative of Vitamin B12 possessing binding activity to Castle's intrinsic factor.

A medicament containing an effective amount of the complex is formulated by mixing the complex with a pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant. The medicament is prepared so as to be suitable for administration to a patient requiring treatment such as one or more of the conditions outlined in the body of the specification. The medicament is prepared using standard pharmaceutical techniques.

It is recognised that a number of factors will affect the determination of an appropriate dosage for a particular patient. Such factors include the age, weight, sex, general health and concurrent disease states of the patient. The determination of the appropriate dose level for the particular patient is performed by standard pharmaceutical techniques.

The medicament is orally administered to the patient in an amount such that an appropriate effective dosage of the substance in the complex contained in the medicament is delivered to the circulation or lymphatic drainage system of the patient.

The invention is further described with reference to the following examples which are in no way limiting on the scope of the invention.

Throughout the following examples, reference to "VB12" is to be taken as reference to Vitamin B12.

EXAMPLE 1

Preparation of microspheres bv Coacervation Almost any protein can be used as the matrix for entrapping drug via the desolvation technique, however preferred proteins according to the invention include bovine serum albumen (BSA), Ovalbumen (OA), collagen, Microspheres were prepared by coacervation of BSA following desolvation, according to the method of Oppenheim (Oppenheim, 1984, Oppenheim et al 1984, 1982), Briefly a 40% ammonium sulphate solution was added dropwise to a solution of 1 % BSA containing 0.5% Tween 20 and the turbidity monitored by Kiett readings, until the turbidity rose rapidly. At this point (determined by experimentation) the solution was placed in an ulτra- turrax and 600 ul of glutaraldehyde added to cross-link the nanoparticles. Cross-linking was stopped by the addition of a solution of 12% sodium metabisulfite.

Particles were then washed extensively with distilled water prior to coupling to the amino-derivative of Vitamin B12.

EXAMPLE 2

Incorporation of Neomvcin Sulphate

For incorporation of the antibiotic, neomycin sulphate, neomycin sulphate was dissolved at 10 g/100 ml of the BSATween solution. Desolvation and cross-linking was carried out as described in Example 1.

EXAMPLE 3

Preparation of Insulin Microspheres

Insulin microspheres were prepared in a similar fashion to the BSA microspheres except the initial desolvation was achieved by the dropwise addition of 0.1 N HCI, while resolvation was achieved by the addition of 0.1 N NaOH. EXAMPLE 4 Coupling of microspheres to amino-ethyl-Vitamin B1

The monocarboxylic acid derivative of Vitamin B12 was prepared as previously described by Allen and Majerus (1972). The diamino-ethane derivative of COOH-Vitamin B12 was prepared by reacting N,N-dicyclohexyi carbodiimide with a solution of diamiπoethane (pH 6.5). The amidated derivative was purified by HPLC.

Proteinaceous microspheres were coupled to amino-ethyl Vitamin B1 by reaction with N,N-dicyclohexyl carbodiimide. EXAMPLE 5 Oral feeding

The VB12-microsphere complex can be administered orally by feeding in a solution of 0.1 M carbonate buffer pH 9.5.

Uptake of the VB12-microspheres occurs via the intrinsic factor mediated VB12 uptake mechanism.

EXAMPLE 6

Preparation of VB^Lipid complexes for hvdroohobic insertion into microspheres a) Preparation of VB12-phosphatidyl ethanolamine (VB12-PEA)

Phosphatidylethanolamine (PEA, 100mg) was dissolved in 2 ml chloroform/methanol (50:50, v/v). Monocarboxyl VB12 ("e" isomer) (100 mg) was added to the mixture. The monocarboxylic acid isomer was then cross- linked to the PEA by the addition of 200 mg of the carbodiimide, 1-ethyl-3-(3- dimethylaminopropyOcarbodiimide (EDC or EDAC). The reaction was allowed to proceed for 90 minutes prior to the addition of the VB12-PEA to microspheres. b) Preparation of other complexes between VB^ and an hydrophobic moietv Covalent complexes can be made between analogues of VB12 and almost any aliphatic or aromatic chains or amphipathic molecule containing a water soluble head group suitable for conjugation and a lipid soluble tail suitable for hydrophobic association within an hydrophobic environment. Thus, any lipid (saturated, unsaturated or polyunsaturated) which has a carboxylic acid head group, such as Oleic acid, octanoic acid, linoleic acid or glycerophosphoric acids may be directly conjugated to an amino-VB12 derivative using a suitable carbodiimide (EDAC or dicyclohexylcarbodiimide, for example). Similarly any amphiphathic molecule possessing an amino-group (amino-hexane, amino- decane, amino-dodecane, phosphatidyl-ethanolamine) may be conjugated directly to carboxy-VB12 using carbodiimides.

EXAMPLE 7 Preparation of VBj^-Microspheres bv so/vent evaporation a) Preparation of VB^-PEA-rPolvmethylmethacrylatel microspheres

Polymethyimethacrylate (PMM, PoiysciencesMMW 12,000; 500mg) was dissolved in 2 ml of dichloromethane (DCM). The PMM in DCM was then added dropwise to 20 ml of 0.25% Poiyvinylalcohol (PVA) while homogenizing at 13,500 rpm with a Janke & Kunkel Ultraturrax. After 1 minute, 200 μ\ of VB12-PEA was added and stirred gently overnight. The pink microspheres were then harvested by centrifugation, washed three times with water and lyophilized.

b) Preparation of VB^-fPEA-Polv-lactic acidl microspheres

Poly-lactic acid (PLA, PoiysciencesMMW 50,000; 500mg) was dissolved in 3 ml of DCM and then homogenized into 20 1 % PVA at 13,500 rpm on an Ultraturrax T25 with an S25F probe for 5 minutes. VB12-PEA (400 μ\) was added while the solution was stirred gently. Microspheres were harvested as described above.

c) Preparation of VB^-PEA-rPolv-Hvdroxv-butvrate/valeratel microspheres

Poly-Hydroxy-butyrate/valerate (9% valerate) (ICI; 500 mg) was dissolved in 5 ml of DCM and homogenized into 20 ml 1 % PVA at 13,500 rpm on an Ultraturrax T25 with an S25F probe for 5 minutes. VB12-PEA (400//I) was added and the spheres processed as described in 8b.

EXAMPLE 8

Covalent conjugation of VB to microspheres with surface carboxvl groups A general method for the conjugation of VB12 to the surface of microspheres made from polymers with free carboxyl groups is outlined below.

The specific example utilizes commercially available carboxyl-modified microspheres.

Polysciences Fluoresbrite™ carboxylate Microspheres (2.5% Solids Latex) were obtained from Polysciences in sizes of 0.045um, 0.49um, 2.2um and 9.97um. One ml of each of the preparations was washed extensively with distilled (DW) and resuspended in 200 μ\ of distilled water. To each preparation was added 1 .5 mg aminododecyl VB12 then 5 mg of EDAC. Each preparation was allowed to react overnight, after which unreacted material was removed by repeated washing with DW or by dialysis against DW.

EXAMPLE 9 Surface derivatization of microspheres

Many polymers used in the preparation of microspheres by solvent evaporation do not contain functional groups for direct conjugation to VB12 or its functionalized analogues, however it is possible to modify the surface of the preformed microspheres to introduce functional groups suitable for conjugation to VB12. a) Surface derivatization of Polylactic acid (PLA) microspheres

A preformed PLA microspheres (10 mg) were gently suspended in DW (350 μl) by rotation on a rotary shaker for 2 hours. Hydrazine hydrate (10 μ\) was added and the suspension was shaken overnight at room temperature. The spheres were spun down and repeatedly washed with water by re- suspension and centrifugation. The washing procedure was repeated until the supernatant failed to give a positive hydrazine test (purple colour upon reaction with a solution of trinitrobenzenesulfonate; 1 mg /ml). The spheres were washed a further two times and the wet pellet used directly for conjugation to VB12. b Conjuoation of VB12 to hydrazine modified PLA microspheres

A sample of the hydrazine modified PLA microspheres (3//I wet pellet) was suspended in DW (250//I). Aqueous solutions of the "e" monocarboxylic acid isomer of VB12 ("e"CB12)(10 mg/ml, 400//I) and EDAC (100 mg/ml, 100 μ\) were added and the reaction mixture shaken overnight at room temperature. The suspension was spun down and the supernatant removed. The pellet was washed repeatedly with DW (6 washes). The residual pellet, which was pale pink in colour, was vacuum dried prior to measurement in the IF assay. Two control reactions were performed concurrently with the above conjugation. In the first a 3 mg sample of hydrazine-modified PLA microspheres was treated with the "e"CB12 as described above but DW was used in place of the EDAC solution. In the second control a 2 mg sample of unmodified PLA microspheres was treated with both "e"CB12 and EDAC as described above. For both controls the pellet remaining after repeated washing was a clear white colour with no evidence of any associated VB12. EXAMPLE 10 Intrinsic Factor binding assay

The ability of various VB12-microsphere preparations to bind to porcine intrinsic factor was assessed in an intrinsic factor binding assay. VB12 and VB12-microsphere preparations were diluted out in six-tenfold dilutions in IF buffer (1 mg/ml BSA [B12 and IF deficient; Sigma #A-3902] in 0.1 M Phosphate buffer pH7.5). To 225 μ\ of IF buffer was added 25 μ\ of the above dilutions. Co5Λ B12 (0.25 ml, 0.25 ng in IF buffer) was then added to each sample. Porcine IF (0.25 ml; 1 lU/ml in IF buffer) was then added and the material allowed to incubate at RT for 20 min. BSA-coated charcoal (0.25 ml; 0.5% BSA (B12 and IF free) plus 2.5% charcoal) was added to each sample, vortexed and then centrifuged. The supernatant from each sample was then counted on a gamma counter set for counting Co57. Results were determined as a percentage inhibition of the Co57-VB12 binding.

EXAMPLE 11

Estimation of IF binding activity of Vt\12 microspheres

Microspheres prepared with VB12 surface coating were examined for IF binding as described above. The percentage binding is presented in the table below.

Table 2. IF binding of various VB12-microsphere preparations.

2a. IF binding bv VB-Carboxylate microspheres (See Example 8)

Data is presented as the percentage inhibition of binding of CoS7B12to 2 U 2b. IF binding bv VB12-PEA coated microspheres

2 Data is expressed as the weight of microspheres which could showed equivalent IF binding as 10 ng of VB12-

3 Microspheres prepared as in Example 8. Microspheres prepared as in Example 9.

EXAMPLE 12 Covalent conjugation of Mucosal Immunogens to Fluorescent microspheres Amino-ethyl derivatized Polysciences FiuoresbriteTM carboxylate Microspheres (2.5% Solids Latex) in sizes of 0.045//m, 0.49 m, 2.2/_τn and 9.97//m were prepared by the addition of 500 μ\ of 0.1 M diaminoethane pH 6.5 to 2 mi of spheres suspended to 2.5%. Surface modification was then obtained by the addition of 50 mg of dry EDAC to each preparation. Unreactec material was removed by centrifugation and washing with DW. Finally microspheres were resuspended in 3 ml of DW. The spheres were then separated into 3 X 1 ml aliquots and treated as follows :- a) Conjugation to LTB Amino-ethyl microspheres were activated with glutaraldehyde by the addition of 40 μ\ of a 25% solution of glutaraldehyde plus 100 μ\ of 0.1 M sodium phosphate buffer pH 6.5. After reaction for 20 minutes at room temperature, 100 μ\ of 1 M HCL was added to the spheres which were then washed twice by centrifugation and resuspension in 10 mM HCI. Finally the spheres were resuspended in 1 ml of DW. LTB (2 mg in 1 ml 0.1 M carbonate buffer pH 9.5' was then added and allowed to conjugate to the activated microspheres overnight. Finally the Schiff's base formed during the conjugation was stabilized by reduction with 200 μ\ of cold sodium borohydride for two nours on ice. The microspheres were then washed 3 times in 0.1 M carbonate buffer, pH 9.5, and resuspended in 500 μ I of the same buffer. Microspheres were then stored at 4°C until used for oral feeding. b) Conjugation to K99 oili Glutaraldehyde activated amino-ethyl microspheres (prepared as desribed in Example 13a) were conjugated to K99 piii by the addition of 2 ml of K99 piii (1 mg/ml) plus 100 /I of 0.1 M carbonate buffer and reaction overnight at room temperature. The Schiff's base was reduced and the microspheres washed as described in Example 12a. c) Conjugation to 987P piii

Amino-ethyl microspheres (1 mi) were conjugated to 987P piii (2 mg in 200 μ\ DW) by the addition of 20 mg of EDAC. After reaction overnight the spheres were washed with 0.1 M carbonate buffer, pH 9.5, as described previously.

Example 13

Oral administration of Fiυoresbrite Microspheres conjugated to VB . 987P.

K99 and LTB

Fluoresbrite Microspheres conjugated to VB12, 987P, K99 and LTB were oraliy administered to conscious mice using a suitable feeding needle. At various times after oral administration the mice were killed by cervical dislocation and the small intestines removed surgically. The intestinal contents were then removed by washing the intestines with a solution containing 0.1 % Tween 20 in 0.1 M phosphate buffer pH 7.4. The small intestine was then cut into four sections, filled with embedding media and frozen prior to sectioning in a cryostat. Sections were examined by light microscopy using a ZEISS fluorescent microscope.

Close examination of sections obtained from mice fed microspheres conjugated to either VB12, 987P, K99 or LTB revealed very similar patterns of binding of spheres to the tips of intestinal epithelial cells. Microspheres of sizes 0.047 μm, 0.45 μm and 1.87 μm could be seen clearly adhering to the tips of the epithelial ceils within 2 hours of feeding, regardless of which molecule the microspheres were coated with. The pattern of binding varied somewhat depending upon the coating of the microspheres, thus VB12 coated microspheres were found to bind mainly to the cells of the iieum and lower jejunum, while microspheres coated with LTB were found to bind down the entire length of the small intestine. Microspheres coated with either 987P piii or K99 piii were found to bind most predominantly in the jejunum. In some sections, microspheres of up to 0.45 μm appeared to have entered the body of the epithelial cell.

Example 14- Oral Administration of PLA Microspheres containing l^-^BSA and coated with VB^-PEA

Two preparations of PLA microspheres were synthesized as described previously. Prior to synthesis 1125-BSA was added to the PLA in DCM. VB12- PEA was added to one of the preparations during the solvent evaporation step. Solvent was evaporated overnight, after which the microspheres were washed extensively with distilled water. Microspheres suspended in 0.1 % BSA in saline were then fed to female Swiss mice. At various times after feeding, the mice were bled from the retro-orbital plexus and I125 counts determined in a Beckman gamma counter.

Table 3. Uptake of -25-BSA incorporated into PLA spheres or PLA spheres coated with VB ...-PEA

* Counts are represented as the percentage of counts released from the stomach of mice fed the various microsphere preparations. The data are presented as the average of three mice ± 1 standard deviation.

As can be seen from the data, there was a highly significant increase in the amount of BSA which was taken up into the blood in mice fed VB12-PEA microspheres in comparison to those fed the PLA spheres alone.

INDUSTRIAL APPLICABILITY

The present invention provides a simple and novel technique for the specific protection of active substances comprised within a complex during their transit down the intestine, prior to Intrinsic Factor or mucosai binding protein mediated uptake of the complexes. The invention also provides a method for the amplification of the VB12 uptake system. Thus the present invention provides a simple and novel technique for the specific protection of active substances from enzymatic degradation as well as for amplification of the VB12 uptake system thus enabling a wide range of active agents to be actively absorbed intact from the intestine.

REFERENCES Oppenheim R.C. (1984) in "Polymeric Microparticies" (Guiot, P and Couvreur,

P. Eds.) CRC Press, Boca Raton.

Oppenheim R.C, Gipps, E.M. Forbes, J.F. and Whitehead R.H. (1984) in

"Microspheres and Drug Therapy" (Davis, S.S., Ilium, L., McVie, J.G. and

Tomlinson, E. Eds) Elsevier Science Publishers B.V. Oppenheim, R.C, Stewart, N.F., Gordon, L. and Patel, H.M. (1982) Drug

Devel. Indust. Pharm. 8: 531-546.

Allen, R.H. and Majerus, P.W. (1972) J.Bioi. Chem. 247: 7702-7717.

Claims

Claims:
1. A complex for oral delivery of a substance to the circulation or lymphatic drainage system of a host, comprising: a microparticle coupled to at least one carrier; the carrier being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of the host; the microparticle entrapping or encapsulating the substance whereby the substance is substantially unaffected by intestinal digestive substances of the host; and the microparticle being adapted to release the entrapped or encapsulated substance into the circulation or lymphatic drainage system of the host.
2. A complex for oral delivery of a substance to the circulation or lymphatic drainage system of a host, comprising: a microparticle coupled to at least one carrier; the carrier being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of the host; the microparticle being capable of entrapping or encapsulating the substance whereby the substance is substantially unaffected by intestinal digestive substances of the host; and the microparticle being adapted to release the entrapped or encapsulated substance into the circulation or lymphatic drainage system of the host.
3. A complex according to claim 1 , wherein the microsphere or microcapsule entraps or encapsulates a hormone, drug, immunogen, or DNA or RNA (such as ribozyme) component, molecule or analogue thereof.
4. A complex according to claim 2, wherein the microsphere or microcapsule is capable of entrapping or encapsulating a compound selected from the group consisting of a hormone, drug, immunogen, DNA component, RNA component, DNA molecule, RNA molecule and analogues thereof.
5. A complex according to claim 1 , wherein the carrier molecule is selected from the group consisting of a mucosal binding protein, a bacterial adhesin, a viral adhesin, a toxin binding subunit, a lectin, Vitamin B12 and an analogue of Vitamin B12 possessing binding activity to Castle's intrinsic factor.
6. A complex according to claim 2, wherein the carrier molecule is selected from the group consisting of a mucosal binding protein, a bacterial adhesin, a viral adhesin, a toxin binding subunit, a lectin, Vitamin B12 and an analogue of Vitamin B12 possessing binding activity to Castle's intrinsic factor.
7. A complex according to claim 5 or 6 wherein the carrier is selected from the group consisting of Vitamin B12, an analogue of Vitamin B12
5 possessing binding activity to Castle's intrinsic factor, a lectin, a pilum, a viral haemaggiutinin and a toxin binding subunit.
8. A complex according to claim 1 , wherein the microparticle further comprises a targetting molecule, wherein the targetting molecule is capable of targetting and attaching said complex to a target in a host.
10 9. A complex according to claim 2, wherein the microparticle further comprises a targetting molecule, wherein the targetting molecule is capable of targetting and attaching said complex to a target in a host.
10. A complex according to claim 8 or 9, wherein the targetting molecule is an antibody, lectin, enzyme, binding protein or binding substance, or a binding
15 fragment of an antibody, lectin, enzyme, binding protein or binding substance.
11. A complex according to claim 1 or 2, wherein the microparticle is coupled to a plurality of carriers.
12. A complex according to claim 1 or 2, wherein each microparticle has one carrier coupled thereto.
20 13. A complex according to claim 1 or 2, wherein the coupling is by means of covalent bonding or hydrophobic interaction.
14. A complex according to claim 13, wherein the covalent bonding is by a cross-linking agent.
15. A composition for oral delivery of a substance or substances to the 25 circulation or lymphatic drainage system of a host, comprising a mixture of ε plurality of different complexes according to claim 1.
16. A composition according to claim 15, further comprising a physiologically acceptable carrier, diluent, excipient or adjuvant.
17. A composition for oral delivery of a substance to the circulation or 30 lymphatic drainage system of a host, comprising the complex of claim 1 together with a physiologically acceptable carrier, diluent, excipient or adjuvant.
18. A composition according to claim 16 or 17, wherein the carrier, diluent, excipient or adjuvant is orally and pharmaceutically acceptable.
35 19. A method of orally delivering a substance to the circulation or lymphatic drainage system of a host requiring such substance, comprising: orally administering to the host an effective amount of a . complex according to claim 1.
20. A method of orally delivering a substance to the circulation or lymphatic drainage system of a host requiring such substance, comprising: orally administering to the host an effective amount of a complex according to claim 2. 5
21. A method according to claim 19 or 20, wherein the host is selected from the group consisting of a vertebrate host, a mammal and a human.
22. A method according to claim 19 or 20, wherein said complex comprises at least one carrier coupled to a microsphere or microcapsule, said microsphere or microcapsule comprising a compound selected from the group
10 consisting of a hormone, drug, immunogen, DNA component, RNA component, DNA molecule, RNA molecule and analogues thereof.
23. A process for the production of a complex according to claim 1 or 2, which process comprises one or more of the following steps:
(a) reacting microparticies with a carrier molecule to form the complex; 15 (b) chemically modifying a carrier molecule to provide at least one functional group capable of forming a chemical linkage and reacting a microparticle and the modified carrier molecule to form the complex;
(c) reacting microparticies with at least one cross-linking agent and reacting the reacted microparticies with a carrier molecule to form the complex;
20 (d) reacting a carrier molecule with at least one cross-linking agent and reacting microparticies with the reacted carrier molecule to form the complex;
(e) reacting microparticies and a carrier with at least one cross-linking agent to form the complex;
(f) reacting microparticies with at least one cross-linking agent, reacting a 25 carrier molecule with at least one cross-linking agent and reacting the reacted microparticies and the reacted carrier molecule to form the complex; or
(g) reacting a carrier molecule with a hydrophobic moiety and reacting microparticies with the reacted carrier molecule to form a complex non- covatently bonded by hydrophobic interaction.
30 24. A kit for preparing a complex for oral delivery of a substance to the circulation or lymphatic drainage system of a host, comprising: at least one type of carrier; at least one type of microparticle; means to couple the microparticle to the carrier to form the complex; 35 the carrier being capable of enabling the complex to be transported to the circulation or lymphatic drainage system via the mucosal epithelium of the host; the microparticle entrapping or encapsulating the substance whereby the substance is substantially unaffected by intestinal digestive substances of the host; and the microparticle being adapted to release the entrapped or encapsulated substance into the circulation or lymphatic drainage system of the host.
PCT/AU1992/000141 1991-04-02 1992-04-02 Oral delivery systems for microparticles WO1992017167A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AUPK5385 1991-04-02
AUPK538591 1991-04-02

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
DE1992621568 DE69221568D1 (en) 1991-04-02 1992-04-02 Systems for oral release of microparticles
US07956003 US6159502A (en) 1991-04-02 1992-04-02 Oral delivery systems for microparticles
JP50746492A JP3296817B2 (en) 1991-04-02 1992-04-02 Oral distribution system suitable for fine particles
KR927002963A KR100250390B1 (en) 1991-04-02 1992-04-02 Oral delivery systems for microparticles
DE1992621568 DE69221568T2 (en) 1991-04-02 1992-04-02 Systems for oral release of microparticles
CA 2084194 CA2084194C (en) 1991-04-02 1992-04-02 Oral delivery systems for microparticles
EP19920908034 EP0531497B1 (en) 1991-04-02 1992-04-02 Oral delivery systems for microparticles

Publications (1)

Publication Number Publication Date
WO1992017167A1 true true WO1992017167A1 (en) 1992-10-15

Family

ID=3775309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AU1992/000141 WO1992017167A1 (en) 1991-04-02 1992-04-02 Oral delivery systems for microparticles

Country Status (9)

Country Link
US (1) US6159502A (en)
EP (1) EP0531497B1 (en)
JP (1) JP3296817B2 (en)
KR (1) KR100250390B1 (en)
CA (1) CA2084194C (en)
DE (2) DE69221568D1 (en)
DK (1) DK0531497T3 (en)
ES (1) ES2108111T3 (en)
WO (1) WO1992017167A1 (en)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013803A1 (en) * 1992-01-10 1993-07-22 De Montfort University Drug system
WO1994018955A1 (en) * 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
WO1994027641A1 (en) * 1993-05-24 1994-12-08 Biotech Australia Pty. Limited Amplification of the vitamin b12 uptake system using polymers
WO1994028879A1 (en) * 1993-06-03 1994-12-22 Biotechnology And Biological Sciences Research Council Oral pharmaceutical compositions comprising a protein or peptide, an antibody and polymeric beads
WO1995001186A1 (en) * 1993-06-30 1995-01-12 De Montfort University Drug system
EP0671169A1 (en) * 1994-03-09 1995-09-13 Hoechst Aktiengesellschaft Nanoparticles containing an active agent and a cetal-tartanic acid amides polymer, process for preparation thereof and their use
WO1996004016A1 (en) * 1994-07-29 1996-02-15 Amgen Inc. Conjugates of vitamin b12 and proteins
WO1996013250A1 (en) * 1994-10-27 1996-05-09 Amgem Inc. Compositions for increased bioavailability of orally delivered therapeutic agents
WO1996020698A2 (en) * 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
EP0754699A1 (en) * 1995-02-02 1997-01-22 Kabushiki Kaisha Sangi Completely dissolved bone tissue and method for producing the same
EP0781142A1 (en) * 1994-09-01 1997-07-02 Allied Medical Research Associates Compositions and methods for delivery of polypeptides
US5922323A (en) * 1993-11-08 1999-07-13 Connaught Laboratories Limited Transferrin receptor genes and immunogenic compositions derived therefrom
WO1999047130A1 (en) * 1998-03-13 1999-09-23 Aventis Research & Technologies Gmbh & Co. Kg Nanoparticles, method for producing nanoparticles and use of the same
US5977337A (en) * 1997-06-03 1999-11-02 Connaught Laboratories Limited Lactoferrin receptor genes of Moraxella
US5977336A (en) * 1993-03-16 1999-11-02 St. Louis University High molecular weight surface proteins of non-typeable haemophilus
WO1999065529A1 (en) * 1998-06-15 1999-12-23 Alza Corporation Nucleic acid-cobalamin complexes and their use in gene therapy
US6083743A (en) * 1992-11-23 2000-07-04 Connaught Laboratories Limited Haemophilus outer membrane protein
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
EP1086118A1 (en) * 1998-06-12 2001-03-28 Biotech Australia Pty. Limited Vitamin b 12? derivatives and methods for their preparation
WO2002030469A2 (en) * 2000-10-12 2002-04-18 Orchid Chemicals And Pharmaceuticals Limited Beta-lactam antibiotic-polysaccharide complex
US6432669B1 (en) 1998-10-07 2002-08-13 Aventis Pasteur Limited Protective recombinant Haemophilus influenzae high molecular weight proteins
WO2002067995A1 (en) * 2001-02-26 2002-09-06 Council Of Scientific And Industrial Research Carrier systems comprising vitamin b12 - biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines
US6863896B1 (en) 1999-10-26 2005-03-08 Chiron Corporation Plant lectins as mucosal adjuvants
US7118749B2 (en) 1993-11-08 2006-10-10 Connaught Laboratories Limited Transferrin receptor genes
US7241449B1 (en) 1999-04-12 2007-07-10 Aventis Pasteur Limited Transferrin receptor genes of moraxella
EP2133359A2 (en) 1999-03-16 2009-12-16 Sanofi Pasteur Limited Recombinant haemophilus influenzae adhesin proteins
WO2011130716A3 (en) * 2010-04-16 2012-06-28 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6270795B1 (en) 1995-11-09 2001-08-07 Microbiological Research Authority Method of making microencapsulated DNA for vaccination and gene therapy
EP0862419B2 (en) * 1995-11-09 2010-11-17 Microbiological Research Authority Microencapsulated dna for vaccination and gene therapy
US5739313A (en) * 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6916490B1 (en) * 1998-07-23 2005-07-12 UAB Research Center Controlled release of bioactive substances
US8636648B2 (en) 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US20120071710A1 (en) 1999-03-01 2012-03-22 Gazdzinski Robert F Endoscopic smart probe and method
US8068897B1 (en) 1999-03-01 2011-11-29 Gazdzinski Robert F Endoscopic smart probe and method
US7914442B1 (en) 1999-03-01 2011-03-29 Gazdzinski Robert F Endoscopic smart probe and method
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
JP2003535122A (en) * 2000-06-02 2003-11-25 ザイコス インク. Delivery systems for bioactive substances
WO2002055530A3 (en) 2000-10-25 2003-01-23 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
EP1363696A1 (en) * 2001-02-09 2003-11-26 Interag Geometry retainable devices for body cavities
US20040146564A1 (en) * 2001-04-05 2004-07-29 Muriel Subirade Process for making delivery matrix and uses thereof
WO2003026674A1 (en) * 2001-09-28 2003-04-03 Mayo Foundation For Medical Education And Research Coadministration of transport protein with conjugated cobalamin to deliver agents
US7148269B2 (en) * 2002-03-11 2006-12-12 Trustees Of The University Of Pennsylvania Interfacial polymer incorporation of nanotubes
US20040014698A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20040016013A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Transgenic animals produced using oral administration of a genetic agent coupled to a transporting agent
US20040014704A1 (en) * 2002-07-18 2004-01-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent induces tolerance
EP1549296A4 (en) 2002-08-02 2006-08-09 Penwest Pharmaceuticals Co Sustained release formulations of metformin
EP1587524A4 (en) * 2003-01-09 2006-07-26 Arizeke Pharmaceuticals Inc Compositions and methods for targeted biological delivery of molecular carriers
EP1620078A2 (en) * 2003-05-02 2006-02-01 The Board Of Trustees Of The University Of Illinois Biodegradable nanoparticles comprising an aminoglycoside and a polymer like a polysaccharide
WO2005027873A3 (en) * 2003-06-20 2005-06-23 Alnis Biosciences Inc Therapeutic aminoglycoside-containing hydrogel nanoparticles
US20050025825A1 (en) * 2003-07-31 2005-02-03 Xanodyne Pharmacal, Inc. Tranexamic acid formulations with reduced adverse effects
US20090214644A1 (en) * 2003-07-31 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations with reduced adverse effects
CN100444828C (en) 2003-12-11 2008-12-24 同济大学 Preparation method of biodegradable polymer pharmaceutical microsphere
US20050208032A1 (en) * 2004-01-16 2005-09-22 Gonzalo Hortelano Oral administration of therapeutic agent coupled to transporting agent
US20050245614A1 (en) * 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US7947739B2 (en) 2004-03-04 2011-05-24 Ferring B.V. Tranexamic acid formulations
US20090215898A1 (en) * 2004-03-04 2009-08-27 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US20050244495A1 (en) 2004-03-04 2005-11-03 Xanodyne Pharmaceuticals, Inc. Tranexamic acid formulations
US8022106B2 (en) * 2004-03-04 2011-09-20 Ferring B.V. Tranexamic acid formulations
EP1893038A1 (en) * 2005-05-17 2008-03-05 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
WO2007087557A3 (en) 2006-01-24 2007-11-01 Univ Maryland Biotech Inst Surface-layer protein coated microspheres and uses thereof
WO2007085888A1 (en) * 2006-01-27 2007-08-02 Wockhardt Limited Controlled release formulations of methylcobalamin
CN101715342A (en) * 2007-03-19 2010-05-26 因弗拉布洛克制药公司 cobalamin taxane bioconjugates
US20100280117A1 (en) * 2009-04-30 2010-11-04 Xanodyne Pharmaceuticals, Inc. Menorrhagia Instrument and Method for the Treatment of Menstrual Bleeding Disorders
WO2010138193A3 (en) 2009-05-27 2011-06-03 Selecta Biosciences, Inc. Targeted synthetic nanocarriers with ph sensitive release of immunomodulatory agents
EP2582393A4 (en) 2010-05-26 2014-04-02 Selecta Biosciences Inc Dose selection of adjuvanted synthetic nanocarriers
EP2683410A2 (en) 2011-03-08 2014-01-15 Access Pharmaceuticals, Inc. Targeted nanocarrier systems for delivery of actives across biological membranes
WO2013021346A3 (en) * 2011-08-07 2013-06-27 Transgene Biotek Ltd A novel method for peroral delivery of insulin and its analogues for therapeutic usage
WO2015126841A1 (en) 2014-02-18 2015-08-27 Plasmatech Biopharmaceuticals, Inc. Nutritional and therapeutic mucoadhesive formulations
CA2995029A1 (en) * 2015-09-25 2017-03-30 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0036277A2 (en) * 1980-03-12 1981-09-23 The Regents Of The University Of California Covalently bonded liposome-protein-compositions and method of producing them
WO1988000474A1 (en) * 1983-01-06 1988-01-28 Blair Geho W Hepatocyte directed vesicle delivery system
WO1988007365A2 (en) * 1987-04-01 1988-10-06 David F Ranney Biodadhesion drug carriers for endothelial and epithelial uptake and lesional localization of therapeutic and diagnostic agents
WO1989008449A1 (en) * 1988-03-18 1989-09-21 Southern Research Institute Method of potentiating an immune response and composition therefor

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA496632A (en) * 1953-10-06 T. Mccombie John Recovery of vitamin b12
US2446974A (en) * 1944-09-23 1948-08-10 Squibb & Sons Inc Synthesis of a penicillin-protein reaction product
US2595499A (en) * 1948-07-10 1952-05-06 Merck & Co Inc Process for production of vitamin b12
GB665485A (en) * 1949-05-05 1952-01-23 Glaxo Lab Ltd Improvements in or relating to the manufacture of preparations containing the anti-pernicious anaemia factor
US2530416A (en) * 1949-10-06 1950-11-21 Merck & Co Inc Process for recovering vitamin b12
US2576932A (en) * 1950-02-01 1951-12-04 John A Garibaldi Fermentation process for production of vitamin b12
US2646386A (en) * 1951-03-03 1953-07-21 Sewerage Commission Of The Cit Process of preparing vitamin b12-active product from sewage sludge
US2709669A (en) * 1951-06-13 1955-05-31 Merck & Co Inc Process for separating vitamin b12 active substances from contaminants
US2892754A (en) * 1951-12-20 1959-06-30 Organon Process of preparing vitamin b12-intrinsic factor
US2764521A (en) * 1953-01-06 1956-09-25 Leviton Abraham Process for the preparation of concentrates of vitamin b12 active substances
US2823167A (en) * 1955-03-29 1958-02-11 Vitarine Co Inc Stable vitamin b12-containing solution
US2850491A (en) * 1955-07-05 1958-09-02 Ciba Pharm Prod Inc Peptide derivatives and process for their manufacture
US2796383A (en) * 1955-07-08 1957-06-18 Merck & Co Inc Cobalamine analogs and process of preparing the same
US3042588A (en) * 1957-04-04 1962-07-03 Distillers Co Yeast Ltd Process for producing cobalaminpeptide complexes
US2835627A (en) * 1957-07-05 1958-05-20 Lilly Co Eli Stable vitamin b12 solutions
US2917436A (en) * 1957-12-23 1959-12-15 Internat Hormones Inc Production of vitamin b by thermophiles
GB1152461A (en) * 1965-06-16 1969-05-21 Ivan Rolovich New Derivatives of Cobalamins
FR5372M (en) * 1966-02-10 1967-10-16
LU64101A1 (en) * 1970-10-28 1973-05-03
GB1445495A (en) * 1973-04-04 1976-08-11 Zambeletti Spa L Vitamin b12 derivatives having prolonged activity
US3981863A (en) * 1975-02-25 1976-09-21 Micromedic Diagonistics, Inc. Cyanocobalamin derivatives
US4133951A (en) * 1975-05-08 1979-01-09 The Radiochemical Centre Limited Vitamin B-12 cobalt-57 and process
DE2546474A1 (en) * 1975-10-17 1977-04-21 Murray M D Israel Cholesterol-lowering thyroxine parenteral preparations - also contg. vitamin B12 to eliminate side effects
FR2373285B1 (en) * 1976-11-25 1979-03-30 Roussel Uclaf
DE2718700A1 (en) * 1977-04-27 1978-11-02 Hans A Dipl Chem Dr Thoma A process for the overall determination of hormones and
US4209614A (en) * 1978-05-30 1980-06-24 E. R. Squibb & Sons, Inc. Vitamin B12 derivative suitable for radiolabeling
US4360358A (en) * 1980-03-07 1982-11-23 Yash Sharma Immunoassay with solid phase having coating containing blood platelet substitute
EP0067921B1 (en) * 1981-06-22 1987-11-11 Prutec Limited A method for determining bioactive substances
DE3262956D1 (en) * 1981-06-22 1985-05-15 Technicon Instr Labelled vitamin b12 derivatives, their preparation and use
US4454125A (en) * 1982-04-22 1984-06-12 Demopoulos Harry B Dry powder formulations having improved flow and compressibility characteristics, and method for the preparation thereof
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
GB2146525B (en) * 1983-09-14 1987-01-14 Univ Ramot Drug delivery system
ES8900006A1 (en) * 1985-05-15 1988-10-16 Biotech Australia Pty Ltd A process for preparing a complex of immunogen
CA1330791C (en) * 1985-10-10 1994-07-19 Gregory John Russell-Jones Oral delivery system
US4952995A (en) * 1986-05-08 1990-08-28 Santa Barbara Research Center Infrared imager
US4839175A (en) * 1986-07-28 1989-06-13 Liposome Technology, Inc. Liposomes with enhanced retention on mucosal tissue
US4751285A (en) * 1986-10-09 1988-06-14 Toohey John I Derivative of cobalamin containing persulfide sulfur and glutathione
GB8826116D0 (en) * 1988-11-08 1988-12-14 Danbiosyst Ltd Adhesive drug delivery composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0036277A2 (en) * 1980-03-12 1981-09-23 The Regents Of The University Of California Covalently bonded liposome-protein-compositions and method of producing them
WO1988000474A1 (en) * 1983-01-06 1988-01-28 Blair Geho W Hepatocyte directed vesicle delivery system
WO1988007365A2 (en) * 1987-04-01 1988-10-06 David F Ranney Biodadhesion drug carriers for endothelial and epithelial uptake and lesional localization of therapeutic and diagnostic agents
WO1989008449A1 (en) * 1988-03-18 1989-09-21 Southern Research Institute Method of potentiating an immune response and composition therefor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0531497A4 *

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993013803A1 (en) * 1992-01-10 1993-07-22 De Montfort University Drug system
US5830506A (en) * 1992-01-10 1998-11-03 De Montfort University Method of making a reversible gel drug delivery vehicle
US6264954B1 (en) 1992-11-23 2001-07-24 Aventis Pasteur Limited Haemophilus outer membrane protein
US6083743A (en) * 1992-11-23 2000-07-04 Connaught Laboratories Limited Haemophilus outer membrane protein
WO1994018955A1 (en) * 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
US5620708A (en) * 1993-02-22 1997-04-15 Alza Corporation Compositions and methods for the oral delivery of active agents
US5702727A (en) * 1993-02-22 1997-12-30 Alza Corporation Compositions and methods for the oral delivery of active agents
US5977336A (en) * 1993-03-16 1999-11-02 St. Louis University High molecular weight surface proteins of non-typeable haemophilus
WO1994027641A1 (en) * 1993-05-24 1994-12-08 Biotech Australia Pty. Limited Amplification of the vitamin b12 uptake system using polymers
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
WO1994028879A1 (en) * 1993-06-03 1994-12-22 Biotechnology And Biological Sciences Research Council Oral pharmaceutical compositions comprising a protein or peptide, an antibody and polymeric beads
WO1995001186A1 (en) * 1993-06-30 1995-01-12 De Montfort University Drug system
US6410053B1 (en) 1993-06-30 2002-06-25 De Montfort University Reversible cross-linked gel
US5902607A (en) * 1993-06-30 1999-05-11 De Montfort University Reversible cross-linked gel
US5922841A (en) * 1993-11-08 1999-07-13 Connaught Laboratories Limited Recombinantly produced transferrin receptor of haemophilus
US7118749B2 (en) 1993-11-08 2006-10-10 Connaught Laboratories Limited Transferrin receptor genes
US6008326A (en) * 1993-11-08 1999-12-28 Connaught Laboratories Limited Transferrin receptor antibodies
US6015688A (en) * 1993-11-08 2000-01-18 Connaught Laboratories Limited Transferrin receptor genes
US5922562A (en) * 1993-11-08 1999-07-13 Connaught Laboratories Limited Nucleic acids encoding transferrin receptors
US5922323A (en) * 1993-11-08 1999-07-13 Connaught Laboratories Limited Transferrin receptor genes and immunogenic compositions derived therefrom
US6262016B1 (en) 1993-11-08 2001-07-17 Connaught Laboratories Limited Transferrin receptor genes
EP0671169A1 (en) * 1994-03-09 1995-09-13 Hoechst Aktiengesellschaft Nanoparticles containing an active agent and a cetal-tartanic acid amides polymer, process for preparation thereof and their use
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
WO1996004016A1 (en) * 1994-07-29 1996-02-15 Amgen Inc. Conjugates of vitamin b12 and proteins
US5843887A (en) * 1994-09-01 1998-12-01 Allied Medical Research Associates Compositions for delivery of polypeptides, and methods
EP0781142A1 (en) * 1994-09-01 1997-07-02 Allied Medical Research Associates Compositions and methods for delivery of polypeptides
EP0781142A4 (en) * 1994-09-01 2003-04-09 Allied Medical Res Associates Compositions and methods for delivery of polypeptides
WO1996013250A1 (en) * 1994-10-27 1996-05-09 Amgem Inc. Compositions for increased bioavailability of orally delivered therapeutic agents
WO1996020698A3 (en) * 1995-01-05 1998-01-22 Univ Michigan Surface-modified nanoparticles and method of making and using same
WO1996020698A2 (en) * 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
US5897881A (en) * 1995-02-02 1999-04-27 Kabushiki Kaisha Sangi Hard tissue intactly dissolved materials and method for producing the same
EP0754699A4 (en) * 1995-02-02 1997-02-26
EP0754699A1 (en) * 1995-02-02 1997-01-22 Kabushiki Kaisha Sangi Completely dissolved bone tissue and method for producing the same
US6143037A (en) * 1996-06-12 2000-11-07 The Regents Of The University Of Michigan Compositions and methods for coating medical devices
US6184371B1 (en) 1997-06-03 2001-02-06 Connaught Laboratories Limited Lactoferrin receptor genes of Moraxella
US5977337A (en) * 1997-06-03 1999-11-02 Connaught Laboratories Limited Lactoferrin receptor genes of Moraxella
WO1999047130A1 (en) * 1998-03-13 1999-09-23 Aventis Research & Technologies Gmbh & Co. Kg Nanoparticles, method for producing nanoparticles and use of the same
EP1086118A1 (en) * 1998-06-12 2001-03-28 Biotech Australia Pty. Limited Vitamin b 12? derivatives and methods for their preparation
EP1086118A4 (en) * 1998-06-12 2002-05-02 Biotech Australia Pty Ltd Vitamin b 12? derivatives and methods for their preparation
WO1999065529A1 (en) * 1998-06-15 1999-12-23 Alza Corporation Nucleic acid-cobalamin complexes and their use in gene therapy
US6849447B2 (en) 1998-10-07 2005-02-01 Aventis Pasteur Limited Protective recombinant Haemophilus influenzae high molecular weight proteins
US6432669B1 (en) 1998-10-07 2002-08-13 Aventis Pasteur Limited Protective recombinant Haemophilus influenzae high molecular weight proteins
EP2133359A2 (en) 1999-03-16 2009-12-16 Sanofi Pasteur Limited Recombinant haemophilus influenzae adhesin proteins
US7241449B1 (en) 1999-04-12 2007-07-10 Aventis Pasteur Limited Transferrin receptor genes of moraxella
US6863896B1 (en) 1999-10-26 2005-03-08 Chiron Corporation Plant lectins as mucosal adjuvants
WO2002030469A3 (en) * 2000-10-12 2003-02-27 Orchid Chemicals & Pharm Ltd Beta-lactam antibiotic-polysaccharide complex
WO2002030469A2 (en) * 2000-10-12 2002-04-18 Orchid Chemicals And Pharmaceuticals Limited Beta-lactam antibiotic-polysaccharide complex
GB2374010A (en) * 2001-02-26 2002-10-09 Council Scient Ind Res Novel vitamin B12 - biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
WO2002067995A1 (en) * 2001-02-26 2002-09-06 Council Of Scientific And Industrial Research Carrier systems comprising vitamin b12 - biodegradable micro particulate conju gates for peroral delivery of drugs, peptides/proteins and vaccines
GB2374010B (en) * 2001-02-26 2004-12-29 Council Scient Ind Res Novel vitamin B12 - biodegradable micro particulate conjugate carrier systems for peroral delivery of drugs, therapeutic peptides/proteins and vaccines
WO2011130716A3 (en) * 2010-04-16 2012-06-28 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers

Also Published As

Publication number Publication date Type
DK0531497T3 (en) 1998-03-23 grant
EP0531497B1 (en) 1997-08-13 grant
ES2108111T3 (en) 1997-12-16 grant
JPH05507941A (en) 1993-11-11 application
US6159502A (en) 2000-12-12 grant
CA2084194A1 (en) 1992-10-03 application
DE69221568T2 (en) 1998-03-19 grant
EP0531497A1 (en) 1993-03-17 application
JP3296817B2 (en) 2002-07-02 grant
CA2084194C (en) 2003-05-20 grant
DE69221568D1 (en) 1997-09-18 grant
KR100250390B1 (en) 2000-05-01 grant
EP0531497A4 (en) 1993-12-22 application

Similar Documents

Publication Publication Date Title
Sarmento et al. Oral insulin delivery by means of solid lipid nanoparticles
Damge et al. Nanocapsules as carriers for oral peptide delivery
Okada et al. Biodegradable microspheres in drug delivery
Jahanshahi et al. Protein nanoparticle: a unique system as drug delivery vehicles
US5736161A (en) Pharmaceutical preparation for improving the bioavailability of drugs which are difficult to absorb and a procedure for obtaining it
Gref et al. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres
Lohcharoenkal et al. Protein nanoparticles as drug delivery carriers for cancer therapy
US5952232A (en) Expandible microparticle intracellular delivery system
US7727969B2 (en) Controlled release nanoparticle having bound oligonucleotide for targeted delivery
Olivier Drug transport to brain with targeted nanoparticles
US5449720A (en) Amplification of the VB12 uptake system using polymers
Ponchel et al. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract
Yin et al. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin
US5100669A (en) Polylactic acid type microspheres containing physiologically active substance and process for preparing the same
Vilar et al. Polymers and drug delivery systems
Mahapatro et al. Biodegradable nanoparticles are excellent vehicle for site directed in-vivo delivery of drugs and vaccines
US5108759A (en) Endothelial envelopment drug carriers
Almeida et al. Solid lipid nanoparticles as a drug delivery system for peptides and proteins
Verrecchia et al. Non-stealth (poly (lactic acid/albumin)) and stealth (poly (lactic acid-polyethylene glycol)) nanoparticles as injectable drug carriers
US20130236556A1 (en) Compositions and methods relating to reduced mucoadhesion
US6645525B1 (en) Ionically formulated biomolecule microcarriers
US20080166414A1 (en) Drugs And Gene Carrier Particles That Rapidly Move Through Mucous Barriers
Fahmy et al. Surface modification of biodegradable polyesters with fatty acid conjugates for improved drug targeting
US6572894B2 (en) Process for the production of morphologically uniform microcapsules and microcapsules that are produced according to this process
US5620708A (en) Compositions and methods for the oral delivery of active agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

WWE Wipo information: entry into national phase

Ref document number: 1992908034

Country of ref document: EP

ENP Entry into the national phase in:

Ref country code: CA

Ref document number: 2084194

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2084194

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1992908034

Country of ref document: EP

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: UA

WWG Wipo information: grant in national office

Ref document number: 1992908034

Country of ref document: EP